Disclosed are methods for screening a drug for treating obesity-related diseases by using the ability of candidate drugs to inhibit the function of pentraxin-4 as an index, and a pharmaceutical composition for treating obesity-related diseases comprising a pentraxin-4 inhibitor as an active ingredient. The drug screened by the above-mentioned method and the pharmaceutical composition are useful for treating obesity-related diseases, particularly for non-alcoholic steatohepatitis (NASH).
